Alkem Laboratories

Alkem Laboratories Equity

The The Equity of Alkem Laboratories (ALKEM.NS) as of Nov 4, 2026 is 138.20 B INR. In the previous year, The Equity was 119.85 B INR — a change of 15.31% (higher).

Equity

138.20 BINR

YoY

15.31%

Last updated:

In 2026, Alkem Laboratories's equity was 138.20 B INR, a 15.31% increase from the 119.85 B INR equity in the previous year.

The Alkem Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
54.39 B INR
Jan 1, 2020
61.61 B INR
Jan 1, 2021
73.77 B INR
Jan 1, 2022
86.38 B INR
Jan 1, 2023
90.45 B INR
Jan 1, 2024
103.12 B INR
Jan 1, 2025
119.85 B INR
Jan 1, 2026
138.20 B INR
The Alkem Laboratories Equity history
YEAREquityYoY
138.20 BINR+15.31%
119.85 BINR+16.22%
103.12 BINR+14.00%
90.45 BINR+4.72%
86.38 BINR+17.10%
73.77 BINR+19.74%
61.61 BINR+13.26%
54.39 BINR+11.83%
48.64 BINR+8.87%
44.68 BINR+21.01%
36.92 BINR+23.10%
29.99 BINR+12.95%
26.55 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Alkem Laboratories's Equity

Alkem Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Alkem Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Alkem Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Alkem Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Alkem Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Alkem Laboratories stock

The Equity of Alkem Laboratories is 138.20 B INR in 2026.

The Equity of Alkem Laboratories changed from 119.85 B INR to 138.20 B INR, representing a 15.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Alkem Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Alkem Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Alkem Laboratories